Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatocellular Carcinoma
100%
Taiwan
69%
95% Confidence Interval
29%
Hepatitis C Virus
25%
Hazard Ratio
25%
Taiwanese
23%
Hepatitis C
20%
Hepatocellular Carcinoma Patient
20%
Overall Survival
20%
Chronic Hepatitis C
20%
Migraine
20%
Cirrhosis
19%
Mesenchymal Stem Cells
17%
Endothelial Progenitor Cells
16%
Risk Factors
16%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
16%
Fabry Disease
16%
Clinical Outcomes
15%
Transarterial Chemoembolization
14%
Reversible Cerebral Vasoconstriction Syndrome
14%
Hepatitis B Virus
14%
National Cohort Study
13%
Human Immunodeficiency Virus Type 1 (HIV-1)
13%
Hepatitis B Surface Antigen (HBsAg)
13%
Enzyme Replacement Therapy
12%
Head-and-neck Cancer
12%
Chronic Hepatitis B
12%
Multivariate Analysis
12%
Ruptured Abdominal Aortic Aneurysm (rAAA)
12%
Albumin-bilirubin Grade
12%
Radiofrequency Ablation
11%
Human Mesenchymal Stem Cells (hMSCs)
11%
Odds Ratio
11%
Human Endothelial Progenitor Cells
10%
Chronic Migraine
10%
Chronic Kidney Disease
10%
Direct-acting Antivirals
10%
High Risk
10%
Taipei
10%
Epithelial-mesenchymal Transition
10%
Hepatitis C Virus Infection
9%
Headache
9%
Tumor
9%
Chemotherapy
9%
Sustained Virological Response
9%
Surgical Resection
9%
Newborn Screening
9%
Alpha-fetoprotein
9%
Photosystem II
8%
Prognostic Factors
8%
Liver
8%
Hepatocellular Carcinoma Risk
8%
Cardiovascular Events
8%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
8%
Hepatitis B
7%
Patient Outcomes
7%
Chronic Hepatitis B Patients
7%
Stem Cells
7%
Gag-Pol
7%
Advanced Hepatocellular Carcinoma
7%
Sofosbuvir
7%
Barcelona Clinic Liver Cancer
7%
Treatment Outcome
7%
Acute Kidney Injury
7%
Angiogenesis
7%
Cox Proportional Hazards Model
7%
Meta-analysis
7%
Hepatitis B e Antigen (HBeAg)
7%
Cancer Cells
7%
Osteogenic Differentiation
6%
COVID-19
6%
Mesenchymal Stromal Cells
6%
Acute Myocardial Infarction
6%
Clinical Manifestations
6%
Major Adverse Cardiovascular Events
6%
Antiretroviral Therapy
6%
Virus
6%
Metastasis
6%
Oxidative Stress
6%
Non-diabetic
6%
Liver Cirrhosis
6%
Cell Function
6%
Estimated Glomerular Filtration Rate
6%
Fabry
6%
Arteriovenous Fistula
6%
Coronary Artery Bypass Grafting
6%
All-cause Mortality
6%
MELD Score
6%
Propensity Score Analysis
6%
Immune Checkpoint Inhibitors
6%
Migraine Patients
6%
General Hospital
6%
Comorbidity
6%
Recurrent Metastatic
6%
Progression-free Survival
6%
Hemodialysis Patients
6%
Serum Levels
6%
Performance Status
6%
Unresectable Hepatocellular Carcinoma (uHCC)
6%
Ischemia
6%
Medicine and Dentistry
Hepatocellular Carcinoma
93%
Overall Survival
23%
Diseases
20%
Hazard Ratio
18%
Neoplasm
17%
Transcatheter Arterial Chemoembolization
17%
Liver Cirrhosis
17%
Endothelial Progenitor Cell
14%
Bilirubin
14%
Migraine
13%
Coronary Artery Disease
13%
Cardiovascular System
12%
Albumin
12%
Fabry Disease
12%
Cohort Analysis
11%
Radiofrequency Ablation
10%
Malignant Neoplasm
10%
Prognostic Factor
10%
Proportional Hazards Model
10%
Odds Ratio
10%
Diabetes Mellitus
10%
Enzyme Replacement Therapy
10%
Head and Neck Squamous Cell Carcinoma
10%
Prevalence
10%
Hepatitis B Virus
9%
Liver Cancer
9%
Hepatitis C Virus
9%
Multivariate Analysis
9%
Chronic Hepatitis C
9%
Headache
8%
Chronic Kidney Disease
8%
Mesenchymal Stem Cell
8%
Chronic Hepatitis B
8%
Aortic Dissection
8%
Biological Marker
8%
Kidney Function
7%
Newborn Screening
7%
Cancer Staging
7%
Cardiovascular Disease
7%
Mucopolysaccharidosis
7%
Chemotherapy
7%
Infection
7%
Liver Disease
7%
Recurrent Disease
7%
Myocardial Infarction
7%
Survival Rate
7%
Hemodialysis
7%
Fibrosis
7%
Endovascular Aneurysm Repair
6%
Computer Assisted Tomography
6%
Acute Kidney Injury
6%
Glycogen Storage Disease Type II
6%
Milan Criteria
6%
Arteriovenous Fistula
6%
Coronary Artery Bypass Graft
6%
Cisplatin
6%
Hepatitis C
6%
Long-Term Outcome
6%
Head and Neck Cancer
5%
Reversible Cerebral Vasoconstriction Syndrome
5%
Stent-Graft
5%
Creatinine
5%
Adverse Event
5%
Immune Checkpoint Inhibitor
5%
Genetics
5%
Retrospective Study
5%
Progression Free Survival
5%
Abdominal Aortic Aneurysm
5%
Squamous Cell Carcinoma
5%
Model for End-Stage Liver Disease
5%
Hepatitis B
5%
Antiviral Therapy
5%
Glomerular Filtration Rate
5%
Tumor
5%
Angiogenesis
5%
Cancer
5%
Platelet
5%
Treatment Outcome
5%
Percutaneous Coronary Intervention
5%
Cetuximab
5%